Anumana partners with Novartis for AI-driven heart disease detection
Related Articles
Anumana Appoints Maulik Nanavaty as CEO
Anumana Appoints Maulik Nanavaty as CEOCAMBRIDGE, Mass. – October 19, 2023 – Anumana, Inc., a leading AI-driven health technology company and portfolio company of nference, today announced that Maulik Nanavaty…October 19, 2023
Anumana Receives U.S. FDA 510(k) Clearance for ECG-AI Algorithm to Detect Low Ejection Fraction
Based on pioneering research from Mayo Clinic, ECG-AI LEF aims to aid physicians in identifying low ejection fraction in patients at risk of heart failureOctober 02, 2023
Mayo Clinic finds algorithm helped clinicians detect heart disease, as part of broader AI diagnostics push
Med City News: Mayo Clinic shared results of a study showing that an AI tool developed by the system could be used to improve diagnosis of low ejection fraction, a…May 08, 2021
Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence
Novartis Pharmaceuticals Corporation to collaborate on development of new medical device software for earlier detection and intervention in cardiovascular diseaseJuly 12, 2022